← Eichor
Condition: Gastric Cancer Or Gastroesophageal Junction Adenocarcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Gastric Cancer Or Gastroesophageal Junction Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-posit
Phase N/A · 36 location(s) · Daiichi Sankyo · NCT06846996Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase II
Phase 3 · 1 location(s) · Fujian Cancer Hospital · NCT06793917A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06415669Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07026149Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fet
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT07289997First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinom
Phase 2/Phase 3 · 12 location(s) · RemeGen Co., Ltd. · NCT06221748Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastri
Phase 2 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06947291Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT04342910M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1
Phase 3 · 1 location(s) · FutureGen Biopharmaceutical (Beijing) Co., Ltd · NCT06177041A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced So
Phase 1 · 30 location(s) · Coherus Oncology, Inc. · NCT06657144A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gast
Phase 2 · 70 location(s) · AstraZeneca · NCT07069712BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer
Phase 1 · 1 location(s) · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · NCT06773312T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT05894824Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 · 11 location(s) · RemeGen Co., Ltd. · NCT06155383Registry Platform Gastric/Esophageal Cancer (SAPHIR)
Phase N/A · 1 location(s) · iOMEDICO AG · NCT04290806Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta
Phase 3 · 286 location(s) · AstraZeneca · NCT07431281Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemo
Phase 3 · 106 location(s) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07385703First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2 · 20 location(s) · Qilu Hospital of Shandong University · NCT06730373QL1706 Combined With SOX Used in Theperioperative Treatment
Phase 1/Phase 2 · 1 location(s) · Xiangdong Cheng · NCT06766305Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ
Phase 3 · 1 location(s) · Fudan University · NCT04997837Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · 21 location(s) · I-Mab Biopharma US Limited · NCT04900818Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric
Phase 1/Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT07334431Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenoca
Phase 2 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07102901A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab Wi
Phase 3 · 1 location(s) · RemeGen Co., Ltd. · NCT07315750Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Te
Phase 1/Phase 2 · 105 location(s) · Boehringer Ingelheim · NCT06324357Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Va
NA · 1 location(s) · Fujian Cancer Hospital · NCT07142122A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combinatio
Phase 2/Phase 3 · 161 location(s) · Bristol-Myers Squibb · NCT07221149A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal
Phase 1 · 46 location(s) · Astellas Pharma Global Development, Inc. · NCT05365581
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.